smalllogo.GIF (10091 bytes)

events.GIF (3325 bytes)
Opening Session
Sunday, February 1, 1998
(5:00 p.m. to 7:00 p.m.)		 Bernard S. Fields Memorial Lecture, Measures of Reality
Ashley Haase, Univ. of Minnesota Med. Sch.

Keynote Lecture, The Challenge of Making an AIDS Vaccine
David Baltimore, California Inst. of Technology

  
events.GIF (3441 bytes) gray.GIF (51 bytes) Time Monday
Feb. 2, 1998		 Tuesday
Feb. 3, 1998		 Wednesday
Feb. 4, 1998		 Thursday
Feb. 5, 1998
state.GIF (680 bytes) 8:30 a.m.
to
9:00 a.m.		 Session 2.
HIV-1 Entry into Cells: Targets for Drug and Vaccine Development
Lecturer:
Joseph Sodroski,
Dana-Farber Cancer Inst.		 white.GIF (54 bytes) white.GIF (54 bytes) Special Symposium
8:30 a.m.
to
10:00 a.m.
9:00 a.m.
to
9:30 a.m.		 Session 3.
Monitoring the Epidemic of HIV/AIDS in the United States:  Currect Status and Future Prospects
Lecturer:
Kevin DeCock,
CDC		 Session 35.
HIV Infection:  The Body Fights Back
Lecturer:
Bruce D. Walker,
Massachusetts Gen. Hosp.		 Session 63.
HIV Drug Discovery:  Issues and Challenges
Lecturer:
Gary Tarpley,
Pharmacia & Upjohn		 Session 96.
Antiretroviral Therapeutics: 
Current Issues
Convener:
Robert Schooley,
Univ. of Colorado Health Sciences Ctr.
9:30 a.m.
to
10:00 a.m.		 Session 4.
Immunopathogenesis of Primate Immunodeficiency Virus Interactions
Lecturer:
Norman Letvin,
Harvard Med. Sch./Beth Israel Deaconess Med. Ctr.		 Session 36.
HHV8-KSHV
Lecturer:
Donald Ganem,
Univ. of California,
San Francisco		 Session 64.
T-Cell Immune Reconstitution in HIV Negative Hosts
Lecturer:
Crystal Mackall,
NCI
slide.GIF (466 bytes) 10:30 a.m.
to
12:30 p.m.		 Slide Session 5.
Antiretroviral Chemotherapy

Slide Session 6.
Epidemiology

Slide Session 7.
Immunopathogenesis of HIV-1 Infection

Slide Session 8.
Virology I

 Slide Session 37.
Pathogenesis, Prophylaxis, and Treatment of Opportunistic Infections

Slide Session 38.
Pathogenesis of Vertical HIV-1 Transmission and Antiretroviral Therapy in HIV-1 Infected Children

Slide Session 39.
Pathogenesis: Lymphocyte Turnover, Co-Receptor Expression, and Primate Studies

Slide Session 40.
Virology II

 Slide Session 65.
Antiretroviral Chemotherapy II

Slide Session 66.
In Vivo Pathogenesis and Primary Infection

Slide Session 67.
KSHV: Biology and Epidemiology

Slide Session 68.
Diagnostic Assays and Viral Quantification

Slide Session 69.
Vaccine Development/Molecular Immunopathogenesis

 Session 97.
Late Breaker Session
sympbar.GIF (404 bytes) 2:00 p.m.
to
4:00 p.m.		 Session 9.
Chemokine Receptors and HIV/SIV
Convener:
Robert Doms,
Univ. of Pennsylvania		 Session 41.
Tissue Reservoirs of HIV
Conveners:
Robert Siliciano,
Johns Hopkins Univ.
and Roger Pomerantz,
Thomas Jefferson Univ.		 Session 70.
Changing Trends in the Epidemiology Pathogenesis of HIV-Related Opportunistic Infections
Conveners:
William Powderly,
Washington Univ.;
Diane Havlir,
Univ. of California, San Diego;
and Constance Benson,
Univ. of Colorado Health Sciences Ctr.		 white.GIF (54 bytes)
Session 10.
AIDS Malignancies
Convener:
Ellen Feigal,
NCI		 Session 42.
Neurologic Aspects of HIV Disease
Convener:
David Clifford,
Washington Univ.		 Session 71.
Biological Mechanisms of Viral Transmission Interruption
Conveners:
Stephen Spector,
Univ. of California, San Diego;
and Thomas C.Quinn,
Johns Hopkins Univ.
Session 11.
Advances in HIV Prevention
Conveners:
Harold Jaffe
and Martha Rogers,
CDC		 Session 43.
HIV Regulatory Proteins and Virus-Host Cell Interactions
Conveners:
George Pavlakis,
NCI-FCRDC,
and Bryan Cullen,
Howard Hughes Med. Inst./Duke Univ. Med. Ctr.		 Session 72.
Accessory Gene Function
Convener:
Mario Stevenson,
Univ. of Massachusetts
special.GIF (272 bytes) 6:30 p.m.
to
8:30 p.m.		 white.GIF (54 bytes) white.GIF (54 bytes) Session 95.
Host Factors in HIV Infection: Implications for Therapy
Convener:
Anthony Fauci,
NIAID
poster.GIF (460 bytes) 4:30 p.m.
to
6:30 p.m.		 12.Chemokines and Their Receptors

13.Effects of Chemokine Receptors on Natural History

14.Viral and Host Determinants of the Natural History of Retroviral Infection

15.Vaccine Development

16.Immune Correlates of Resistance to Retroviral Infections

17.Humoral and Cellular Immunity to HIV-1

18.Miscellaneous Immunology

19.Diagnostics: Viral Diversity

20.Epidemiology: Molecular Subtypes of HIV

21.Epidemiology: Substance Abuse

22.Epidemiology: Infection Control

23.Miscellaneous Epidemiology

24.Antiretroviral Therapy: Practice Patterns, Adherence, and Outcomes

25.Immunologic Effects of Highly Active Antiretroviral Therapy

26.Impact of HAART on the Incidence and Spectrum of Opportunistic Complications

27.Epidemiology: Effects of Therapy on Cost of Care and Hospitalization

28.Epidemiology: Effects of HIV-1Therapy on Cost of Care and Hospitalization

29.Epidemiology: Correlates of Disease Progression and Survival

30.Clinical Trials: Statistical Issues and Predictors of Response

31.Pharmacokinetic Studies of Antiretroviral and Immunolodulatory Drugs in HIV-1 Infected Children and Pregnant Women

32.Antiretroviral Therapy in Neonates, Infants, and Children

33.Pathogenesis and Prevention of Vertical HIV-1 Transmission

34.Immunopathogenesis and Immune Responses in HIV-1 Infected Children and Pregnant Women

 44.HIV Replication: Molecular Regulation, Accessory Proteins, and Assembly

45.HIV Replication: Reverse Transcription and Integration

46.Diagnostics: Viral Load Assays

47.Viral Quantitation During Antiretroviral Therapy

48.Techniques for Assessing Susceptibility to Antiretroviral Drugs

49.Antiretroviral Therapy: Pharmacology and Drug Interactions

50.Combination Antiretroviral Chemotherapy: Nucleoside Analogs and Protease Inhibitors

51.Dual Protease Inhibitor Therapy

52.Resistance to Antiretroviral Protease Inhibitors

53.Antiretroviral Therapy: Unique Adverse Effects of Protease Inhibitors

54.Antiretroviral therapy: Salvage Regimens

55.KSHV

56.Neuropathogenesis of Retroviral Infection

57.HIV Demtia, Peripheral Neuropathy, and Other CNS Complications

58.Neurologic Opportunistic Infections: PML and Toxoplasmosis

59.HIV Wasting/Diarrheal Opportunistic Infections

60.Fungal Opportunistic Infections: Pathogenesis and Treatment

61.Opportunistic Infections: Hepatitis Viruses and Herpesviruses

62.Opportunistic Infections: Miscellaneous

 73.Viral Fitness

74.Retroviral and Cellular Turnover Kinetics

75.Miscellaneous Retrovirology

76.Miscellaneous Pathogenesis

77.Primary HIV-1 Infection

78.Immunology: Cytokines and Immune Regulation

79.Cytokine and Genetic Therapies

80.Genetic Therapies: In Vitro Studies

81.In Vitro Studies of Novel Antiretroviral Agents

82.Novel Antiretroviral Chemotherapeutic Agents

83.Antiviral Chemotherapy: Hydroxyurea

84.Antiretroviral Therapy: Nucleoside Reverse Transcriptase Inhibitors

85.Resistance to Antiretroviral Nucleoside Reverse Transcriptase Inhibitors

86.Combination Chemotherapy: Role of Nonnucleoside Reverse Transcriptase Inhibitors

87.Resistance to Antiretroviral Non-Nucleoside Reverse Transcriptase Inhibitors

88.HIV-1 Replication in the Female Genital Tract

89.HIV Infection in Women: Manifestations, Disease Progression, and Therapy

90.Opportunistic Infections: Mycobacterium avium and Other Atypical Mycobacteria

91.Opportunistic Infections: Mycobacterium tuberculosis Pathogenesis, Prevention, and Treatment

91.Opportunistic Infections: Pneumocystis carinii Pneumonia/ Respiratory and Other Bacterial Infections

92.Cytomegalovirus Infections: Immunopathogenesis, Prognostic Markers, and Disease

93.Cytomegalovirus Infections:   Immunopathogenesis, Prognostic Markers, and Disease

94.Diagnostics: CMV

 white.GIF (54 bytes)

© 5th Conference on Retroviruses and Opportunistic Infections,
Foundation for Retrovirology and Human Health